Redmile Group, LLC Nurix Therapeutics, Inc. Transaction History
Redmile Group, LLC
- $1.53 Billion
- Q2 2024
A detailed history of Redmile Group, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 4,423,616 shares of NRIX stock, worth $103 Million. This represents 6.02% of its overall portfolio holdings.
Number of Shares
4,423,616
Previous 4,483,016
1.33%
Holding current value
$103 Million
Previous $65.9 Million
40.09%
% of portfolio
6.02%
Previous 2.6%
Shares
14 transactions
Others Institutions Holding NRIX
# of Institutions
183Shares Held
66.4MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$159 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.99MShares$93.1 Million2.73% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$90.6 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$84.6 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA3.2MShares$74.7 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.1B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...